Adding GIP/GLP-1 receptor co-agonists:A systematic review and meta-analysis [60] evaluating the efficacy and safety of tirzepatide against placebo or active comparator in people with T2D included six RCT (data from 6579 subjects; 4410 in the tirzepatide group and 2054 in the control group). The gene discussed is GIP; the disease is type 2 diabetes mellitus.